The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

In this video, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, discusses notable updates across several areas of cardiology ...

The company also announced the appointment of its current Executive Chair, Alvin Shih, MD to the Chief Executive Officer role, plus the appointment of Rebecca Luse, Managing Director at Deep Track ...

led to an 18% reduction in cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection fraction, said AZ. Ejection fraction is a measure of how much ...

Heart failure with preserved ejection fraction (HFpEF) is a disease in which the left ventricle (LV) of the heart shows impaired relaxation during cardiac diastole, often accompanied by structural and ...

While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the specialty ...

Research analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Tenaya Therapeutics in ...

Ferric carboxymaltose, an IV iron replacement therapy, did not reduce the time to first HF hospitalization or CV death for patients with HF and iron deficiency, according to results of a late-breaking ...

Objective Clinical decision making in chronic heart failure (CHF) is based primarily on left ventricular ejection fraction (LVEF), and only secondarily on aetiology of the underlying disease. Our aim ...